`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`Civil Action No. _____
`
`
`
`
`
`
`
`
`
`
`
`
`)
`
`
`
`))
`
`))))))))
`
`
`)
`
`
`ASTRAZENECA AB,
`
`
`
`
`
`Plaintiff,
`
`v.
`
`
`MYLAN PHARMACEUTICALS, INC.,
`
`
`
`Defendants.
`
`COMPLAINT
`
`Plaintiff AstraZeneca AB (“AstraZeneca”), by its attorneys, hereby alleges as
`
`follows:
`
`NATURE OF THE ACTION
`
`1.
`
`This is an action for patent infringement arising under the patent laws of the
`
`United States, Title 35, United States Code, against Defendant Mylan Pharmaceuticals, Inc.
`
`(“Mylan”). This action relates to Abbreviated New Drug Application (“ANDA”) Nos. 205980
`
`and 205981 filed by Mylan with the U.S. Food and Drug Administration (“FDA”).
`
`2.
`
`In ANDA No. 205980, Mylan seeks approval to market 2.5 mg and 5 mg
`
`saxagliptin hydrochloride tablets, generic versions of AstraZeneca’s ONGLYZA® drug product,
`
`prior to expiration of RE44,186 (“the RE’186 patent”) and U.S. Patent No. 7,951,400 (“the ’400
`
`patent”).
`
`3.
`
`In ANDA No. 205981, Mylan seeks approval to market 5 mg/500mg, 2.5
`
`mg/1000 mg and 5 mg/1000 mg saxagliptin hydrochloride and metformin hydrochloride
`
`
`ME1 17982829v.1
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 2 of 13 PageID #: 2
`
`
`
`extended-release tablets, generic versions of AstraZeneca’s KOMBIGLYZE™ XR drug product,
`
`prior to expiration of the RE’186 patent and U.S. Patent No. 8,628,799 (“the ’799 patent”).
`
`PARTIES
`
`4.
`
`Plaintiff AstraZeneca is a company operating and existing under the laws of
`
`Sweden, with its principal place of business at S-151 85 Södertälje, Sweden.
`
`5.
`
`Plaintiff’s subsidiary, AstraZeneca Pharmaceuticals LP, is a limited partnership
`
`operating and existing under the laws of Delaware, with its principal place of business at 1800
`
`Concord Pike, Wilmington, Delaware 19803.
`
`6.
`
`AstraZeneca is engaged in the business of creating, developing, and bringing to
`
`market revolutionary biopharmaceutical products to help patients prevail against serious
`
`diseases, including treatments for Type II diabetes. Through its subsidiary, AstraZeneca
`
`Pharmaceuticals LP, AstraZeneca markets and sells ONGLYZA® and KOMBIGLYZE™ XR in
`
`this judicial district and throughout the United States.
`
`7.
`
`Upon information and belief, Mylan is a company organized and existing under
`
`the laws of West Virginia, having a principal place of business at 781 Chestnut Ridge Road,
`
`Morgantown, West Virginia 26505.
`
`JURISDICTION AND VENUE
`
`8.
`
`This action arises under the patent laws of the United States, 35 U.S.C. §§ 100, et
`
`seq., and this Court has jurisdiction over the subject matter of this action under 28 U.S.C.
`
`§§ 1331, 1338(a), 2201 and 2202.
`
`9.
`
`Venue is proper in this Court under 28 U.S.C. §§ 1391 and 1400(b).
`
`
`
`ME1 17982829v.1
`
`- 2 -
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 3 of 13 PageID #: 3
`
`
`
`10.
`
`This Court has jurisdiction over Mylan because, inter alia, this action arises from
`
`actions of Mylan directed toward Delaware and because Mylan has purposefully availed itself of
`
`the rights and benefits of Delaware law by engaging in systematic and continuous contacts with
`
`Delaware. Mylan regularly and continuously transacts business within the State of Delaware,
`
`including by selling pharmaceutical products in Delaware, either on its own or through its
`
`affiliates. Upon information and belief, Mylan derives substantial revenue from the sale of those
`
`products in Delaware and has availed itself of the privilege of conducting business within the
`
`State of Delaware.
`
`11. Mylan has previously been sued in this judicial district without objecting on the
`
`basis of lack of personal jurisdiction and has availed itself of Delaware courts through the
`
`assertion of counterclaims and by filing suits in Delaware.
`
`12.
`
`For these reasons, and for other reasons that will be presented to the Court if
`
`jurisdiction is challenged, the Court has personal jurisdiction over Mylan.
`
`PATENTS-IN-SUIT
`
`13.
`
`On April 30, 2013, the U.S. Patent and Trademark Office duly and legally
`
`reissued the RE’186 patent, titled “Cyclopropyl-Fused Pyrrolidine-Based Inhibitors of
`
`Dipeptidyl Peptidase IV and Method.” The RE’186 patent is a reissue of U.S. Patent No.
`
`6,395,767 (“the ’767 patent”), which issued on May 28, 2002. A true and correct copy of the
`
`RE’186 patent is attached hereto as Exhibit A. The claims of the RE’186 patent are valid and
`
`enforceable. AstraZeneca is the owner of the RE’186 patent by assignment and has the right to
`
`enforce it.
`
`
`
`ME1 17982829v.1
`
`- 3 -
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 4 of 13 PageID #: 4
`
`
`
`14.
`
`On May 31, 2011, the U.S. Patent and Trademark Office duly and legally issued
`
`the ’400 patent, entitled “Coated Tablet Formulation and Method.” A true and correct copy of
`
`the ’400 patent is attached hereto as Exhibit B. The claims of the ’400 patent are valid and
`
`enforceable. AstraZeneca is the owner of the ’400 patent by assignment and has the right to
`
`enforce it.
`
`15.
`
`On January 14, 2014, the U.S. Patent and Trademark Office duly and legally
`
`issued the ’799 patent, entitled “Coated Tablet Formulation and Method.” A true and correct
`
`copy of the ’799 patent is attached hereto as Exhibit C. The claims of the ’799 patent are valid
`
`and enforceable. AstraZeneca is the owner of the ’799 patent by assignment and has the right to
`
`enforce it.
`
`16.
`
`AstraZeneca is the holder of New Drug Application (“NDA”) No. 022350, by
`
`which the FDA granted approval for the marketing and sale of 2.5 mg and 5 mg strength
`
`saxagliptin hydrochloride tablets as an adjunct to diet and exercise to improve glycemic control
`
`in adults with type 2 diabetes mellitus in multiple clinical settings. AstraZeneca markets
`
`saxagliptin hydrochloride tablets in the United States, through its Delaware subsidiary
`
`AstraZeneca Pharmaceuticals LP, under the trade name “ONGLYZA®.” The FDA’s official
`
`publication of approved drugs (the “Orange Book”) includes ONGLYZA® together with the
`
`RE’186 and ’400 patents.
`
`17.
`
`AstraZeneca is the holder of New Drug Application (“NDA”) No. 200678 by
`
`which the FDA granted approval for the marketing and sale of 5 mg/500 mg, 5 mg/1000 mg and
`
`2.5 mg/1000 mg strength saxagliptin hydrochloride and metformin hydrochloride extended
`
`release tablets as an adjunct to diet and exercise to improve glycemic control in adults with type
`
`
`
`ME1 17982829v.1
`
`- 4 -
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 5 of 13 PageID #: 5
`
`
`
`2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
`
`AstraZeneca markets saxagliptin hydrochloride and metformin hydrochloride tablets in the
`
`United States, through its Delaware subsidiary AstraZeneca Pharmaceuticals LP, under the trade
`
`name “KOMBIGLYZE™ XR.”
`
` The Orange Book
`
`includes 5 mg/500 mg strength
`
`KOMBIGLYZE™ XR together with the RE’186 and ’799 patents. The Orange Book includes 5
`
`mg/1000 mg and 2.5 mg/1000 mg strength KOMBIGLYZE™ XR together with the RE’186
`
`patent.
`
`INFRINGEMENT BY MYLAN
`
`A.
`
`Submission of ANDA No. 205980
`
`18.
`
`By letter dated April 28, 2014, Mylan notified AstraZeneca that Mylan had
`
`submitted ANDA No. 205980 to the FDA under Section 505(j) of the Federal Food, Drug, and
`
`Cosmetic Act (21 U.S.C. § 355(j)) (“the Onglyza Notice Letter”). AstraZeneca received the
`
`Onglyza Notice Letter on or about April 30, 2014.
`
`19.
`
`The Onglyza Notice Letter states that Mylan seeks approval from the FDA to
`
`engage in the commercial manufacture, use, and sale of generic saxagliptin hydrochloride tablets
`
`before the expiration of the RE’186 and ’400 patents. Upon information and belief, Mylan
`
`intends to engage in the commercial manufacture, use, and sale of its generic saxagliptin
`
`hydrochloride tablets promptly upon receiving FDA approval to do so.
`
`20.
`
`By filing ANDA No. 205980, Mylan has necessarily represented to the FDA that
`
`its generic saxagliptin hydrochloride tablets have the same active ingredient as ONGLYZA®,
`
`have the same method of administration, dosage form, and strengths as ONGLYZA®, and are
`
`bioequivalent to ONGLYZA®.
`
`
`
`ME1 17982829v.1
`
`- 5 -
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 6 of 13 PageID #: 6
`
`
`
`21.
`
`In the Onglyza Notice Letter, Mylan states that its ANDA contains a “Paragraph
`
`IV certification” asserting that the RE’186 and ’400 patents are invalid, unenforceable and/or
`
`will not be infringed by the commercial manufacture, use, and sale of Mylan’s generic
`
`saxagliptin hydrochloride tablets.
`
`22.
`
`This Complaint is being filed before the expiration of the forty-five days from the
`
`date AstraZeneca received the Onglyza Notice Letter.
`
`B.
`
`Submission of ANDA No. 205981
`
`23.
`
`By letter dated April 28, 2014, Mylan notified AstraZeneca that Mylan had
`
`submitted ANDA No. 205981 to the FDA under Section 505(j) of the Federal Food, Drug, and
`
`Cosmetic Act (21 U.S.C. § 355(j)) (“the Kombiglyze Notice Letter”). AstraZeneca received the
`
`Kombiglyze Notice Letter on or about April 30, 2014.
`
`24.
`
`The Kombiglyze Notice Letter states that Mylan seeks approval from the FDA to
`
`engage in the commercial manufacture, use, and sale of generic saxagliptin hydrochloride and
`
`metformin hydrochloride extended-release tablets before the expiration of the RE’186 and ’799
`
`patents. Upon information and belief, Mylan intends to engage in the commercial manufacture,
`
`use, and sale of its generic saxagliptin hydrochloride and metformin hydrochloride extended-
`
`release tablets promptly upon receiving FDA approval to do so.
`
`25.
`
`By filing ANDA No. 205981, Mylan has necessarily represented to the FDA that
`
`its generic saxagliptin hydrochloride and metformin hydrochloride extended-release tablets have
`
`the same active ingredient as KOMBIGLYZE™ XR, have the same method of administration,
`
`dosage form, and strengths as KOMBIGLYZE™ XR, and are bioequivalent to KOMBIGLYZE™
`
`XR.
`
`
`
`ME1 17982829v.1
`
`- 6 -
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 7 of 13 PageID #: 7
`
`
`
`26.
`
`In the Kombiglyze Notice Letter, Mylan states that its ANDA contains a
`
`“Paragraph IV certification” asserting that the RE’186 and ’799 patents are invalid,
`
`unenforceable and/or will not be infringed by the commercial manufacture, use, and sale of
`
`Mylan’s generic saxagliptin hydrochloride and metformin hydrochloride extended-release
`
`tablets.
`
`27.
`
`This Complaint is being filed before the expiration of the forty-five days from the
`
`date AstraZeneca received the Kombiglyze Notice Letter.
`
`COUNT I (INFRINGEMENT OF THE RE’186 PATENT) (ANDA NO. 205980)
`
`28.
`
`Each of the preceding paragraphs 1 to 27 is incorporated as if fully set forth
`
`herein.
`
`29. Mylan’s submission of ANDA No. 205980 to obtain approval to engage in the
`
`commercial manufacture, use, offer to sell, or sale of generic saxagliptin hydrochloride tablets
`
`prior to the expiration of the RE’186 patent constituted a technical act of infringement. Upon
`
`information and belief, the product described in ANDA No. 205980 would infringe one or more
`
`of the claims of the RE’186 patent under 35 U.S.C. § 271(e)(2)(A).
`
`30.
`
`Upon information and belief, upon FDA approval of Mylan’s ANDA No. 205980,
`
`Mylan will further infringe at least one claim of the RE’186 patent by making, using, offering to
`
`sell, and selling its generic saxagliptin hydrochloride tablets in the United States and/or
`
`importing such tablets into the United States, and by actively inducing and contributing to
`
`infringement by others, in violation of 35 U.S.C. § 271(a)-(c) unless enjoined by the Court.
`
`
`
`ME1 17982829v.1
`
`- 7 -
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 8 of 13 PageID #: 8
`
`
`
`31.
`
`If Mylan’s marketing and sale of generic saxagliptin hydrochloride tablets prior to
`
`expiration of the RE’186 patent and all other relevant exclusivities is not enjoined, AstraZeneca
`
`will suffer substantial and irreparable harm for which there is no remedy at law.
`
`COUNT II (INFRINGEMENT OF THE ’400 PATENT) (ANDA NO. 205980)
`
`32.
`
`Each of the preceding paragraphs 1 to 31 is incorporated as if fully set forth
`
`herein.
`
`33. Mylan’s submission of ANDA No. 205980 to obtain approval to engage in the
`
`commercial manufacture, use, offer to sell, or sale of generic saxagliptin hydrochloride tablets
`
`prior to the expiration of the ’400 patent constituted a technical act of infringement. Upon
`
`information and belief, the product described in ANDA No. 205980 would infringe one or more
`
`of the claims of the ’400 patent under 35 U.S.C. § 271(e)(2)(A).
`
`34.
`
`Upon information and belief, upon FDA approval of Mylan’s ANDA No. 205980,
`
`Mylan will further infringe at least one claim of the ’400 patent by making, using, offering to
`
`sell, and selling its generic saxagliptin hydrochloride tablets in the United States and/or
`
`importing such tablets into the United States, and by actively inducing and contributing to
`
`infringement by others, in violation of 35 U.S.C. § 271(a)-(c) unless enjoined by the Court.
`
`35.
`
`If Mylan’s marketing and sale of generic saxagliptin hydrochloride tablets prior to
`
`expiration of the ’400 patent and all other relevant exclusivities is not enjoined, AstraZeneca will
`
`suffer substantial and irreparable harm for which there is no remedy at law.
`
`COUNT III (INFRINGEMENT OF THE RE’186 PATENT) (ANDA NO. 205981)
`
`36.
`
`Each of the preceding paragraphs 1 to 35 is incorporated as if fully set forth
`
`herein.
`
`
`
`ME1 17982829v.1
`
`- 8 -
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 9 of 13 PageID #: 9
`
`
`
`37. Mylan’s submission of ANDA No. 205981 to obtain approval to engage in the
`
`commercial manufacture, use, offer to sell, or sale of generic saxagliptin hydrochloride and
`
`metformin hydrochloride extended-release tablets prior to the expiration of the RE’186 patent
`
`constituted a technical act of infringement. Upon information and belief, the product described
`
`in ANDA No. 205981 would infringe one or more of the claims of the RE’186 patent under 35
`
`U.S.C. § 271(e)(2)(A).
`
`38.
`
`Upon information and belief, upon FDA approval of Mylan’s ANDA No. 205981,
`
`Mylan will further infringe at least one claim of the RE’186 patent by making, using, offering to
`
`sell, and selling its generic saxagliptin hydrochloride and metformin hydrochloride extended-
`
`release tablets in the United States and/or importing such tablets into the United States, and by
`
`actively inducing and contributing to infringement by others, in violation of 35 U.S.C. § 271(a)-
`
`(c) unless enjoined by the Court.
`
`39.
`
`If Mylan’s marketing and sale of generic saxagliptin hydrochloride and metformin
`
`hydrochloride extended-release tablets prior to expiration of the RE’186 patent and all other
`
`relevant exclusivities is not enjoined, AstraZeneca will suffer substantial and irreparable harm
`
`for which there is no remedy at law.
`
`COUNT IV (INFRINGEMENT OF THE ’799 PATENT) (ANDA NO. 205981)
`
`40.
`
`Each of the preceding paragraphs 1 to 39 is incorporated as if fully set forth
`
`herein.
`
`41. Mylan’s submission of ANDA No. 205981 to obtain approval to engage in the
`
`commercial manufacture, use, offer to sell, or sale of generic saxagliptin hydrochloride and
`
`metformin hydrochloride extended-release tablets prior to the expiration of the ’799 patent
`
`
`
`ME1 17982829v.1
`
`- 9 -
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 10 of 13 PageID #: 10
`
`
`
`constituted a technical act of infringement. Upon information and belief, at least one dosage
`
`strength of the product described in ANDA No. 205981 would infringe one or more of the claims
`
`of the ’799 patent under 35 U.S.C. § 271(e)(2)(A).
`
`42.
`
`Upon information and belief, upon FDA approval of Mylan’s ANDA No. 205981,
`
`Mylan will further infringe at least one claim of the ’799 patent by making, using, offering to
`
`sell, and selling at least one dosage strength of its generic saxagliptin hydrochloride and
`
`metformin hydrochloride extended-release tablets in the United States and/or importing such
`
`tablets into the United States, and by actively inducing and contributing to infringement by
`
`others, in violation of 35 U.S.C. § 271(a)-(c) unless enjoined by the Court.
`
`43.
`
`If Mylan’s marketing and sale of at least one infringing dosage strength of its
`
`generic saxagliptin hydrochloride and metformin hydrochloride extended-release tablets prior to
`
`expiration of the ’799 patent and all other relevant exclusivities is not enjoined, AstraZeneca will
`
`suffer substantial and irreparable harm for which there is no remedy at law.
`
`PRAYER FOR RELIEF
`
`WHEREFORE, AstraZeneca prays that this Court grant the following relief:
`
`1.
`
`A judgment that the claims of the RE’186 and ’400 patents are not invalid,
`
`not unenforceable, and are infringed by Mylan’s submission of ANDA No. 205980, and that
`
`Mylan’s making, using, offering to sell, or selling in the United States, or importing into the
`
`United States Mylan’s generic saxagliptin hydrochloride tablets will infringe the RE’186 and
`
`’400 patents.
`
`2.
`
`An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective
`
`date of any approval of ANDA No. 205980 shall be a date which is not earlier than the latest
`
`
`
`ME1 17982829v.1
`
`- 10 -
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 11 of 13 PageID #: 11
`
`
`
`expiration date of the RE’186 and ’400 patents, including any extensions and/or additional
`
`periods of exclusivity to which AstraZeneca is or becomes entitled.
`
`3.
`
`An order permanently enjoining Mylan, its affiliates, subsidiaries, and
`
`each of its officers, agents, servants and employees and those acting in privity or concert with
`
`them, from making, using, offering to sell, or selling in the United States, or importing into the
`
`United States Mylan’s generic saxagliptin hydrochloride tablets until after the latest expiration
`
`date of the RE’186 and ’400 patents, including any extensions and/or additional periods of
`
`exclusivity to which AstraZeneca is or becomes entitled.
`
`4.
`
`Damages or other monetary relief to AstraZeneca if Mylan engages in
`
`commercial manufacture, use, offers to sell, sale, or importation in or into the United States of
`
`Mylan’s generic saxagliptin hydrochloride tablets prior to the latest expiration date of the
`
`RE’186 and ’400 patents, including any extensions and/or additional periods of exclusivity to
`
`which AstraZeneca is or becomes entitled.
`
`5.
`
`A judgment that the claims of the RE’186 and ’799 patents are not invalid,
`
`not unenforceable, and are infringed by Mylan’s submission of ANDA No. 205981, and that
`
`Mylan’s making, using, offering to sell, or selling in the United States, or importing into the
`
`United States Mylan’s generic saxagliptin hydrochloride and metformin hydrochloride extended-
`
`release tablets will infringe the RE’186 patent and with regard to at least one dosage strength of
`
`Mylan’s generic saxagliptin hydrochloride and metformin hydrochloride extended-release
`
`tablets, the ’799 patent.
`
`6.
`
`An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective
`
`date of any approval of ANDA No. 205981 shall be a date which is not earlier than the latest
`
`
`
`ME1 17982829v.1
`
`- 11 -
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 12 of 13 PageID #: 12
`
`
`
`expiration date of the RE’186 and ’799 patents, including any extensions and/or additional
`
`periods of exclusivity to which AstraZeneca is or becomes entitled.
`
`7.
`
`An order permanently enjoining Mylan, its affiliates, subsidiaries, and
`
`each of its officers, agents, servants and employees and those acting in privity or concert with
`
`them, from making, using, offering to sell, or selling in the United States, or importing into the
`
`United States Mylan’s generic saxagliptin hydrochloride and metformin hydrochloride extended-
`
`release tablets until after the latest expiration date of the RE’186 and ’799 patents, including any
`
`extensions and/or additional periods of exclusivity to which AstraZeneca is or becomes entitled.
`
`8.
`
`Damages or other monetary relief to AstraZeneca if Mylan engages in
`
`commercial manufacture, use, offers to sell, sale, or importation in or into the United States of
`
`Mylan’s generic saxagliptin hydrochloride and metformin hydrochloride extended-release tablets
`
`prior to the latest expiration date of the RE’186 and ’799 patents, including any extensions
`
`and/or additional periods of exclusivity to which AstraZeneca is or becomes entitled.
`
`9.
`
`Such further and other relief as this Court deems proper and just, including
`
`any appropriate relief under 35 U.S.C. § 285.
`
`
`
`
`
`
`
`ME1 17982829v.1
`
`- 12 -
`
`
`
`Case 1:14-cv-00696-GMS Document 1 Filed 06/02/14 Page 13 of 13 PageID #: 13
`
`DATED: June 2, 2014
`
`
`
`
`
`
`
`
`
`
`
`MCCARTER & ENGLISH, LLP
`
`
`/s/ Michael P. Kelly
`Michael P. Kelly (#2295)
`Daniel M. Silver (#4758)
`Renaissance Centre
`405 N. King Street, 8th Floor
`Wilmington, Delaware 19801
`(302) 984-6300
`mkelly@mccarter.com
`dsilver@mccarter.com
`
`Attorneys for Plaintiff
`AstraZeneca AB
`
`
`
`
`ME1 17982829v.1
`
`- 13 -
`
`